☆ 4.4 Review

How to integrate CD19 specific chimeric antigen receptor T cells with other CD19 targeting agents in diffuse large B-cell lymphoma?

HEMATOLOGICAL ONCOLOGY (2023)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Review Hematology

Targeting CD19 for diffuse large B cell lymphoma in the era of CARs: Other modes of transportation

David Sermer et al.

Summary: CD19 is widely present on B-lymphocytes and B-cell malignancies. CD19-directed CAR T cells have improved outcomes in B-cell malignancies, but there are limitations. CD19 can also be targeted by other drugs, but optimal patient selection and sequencing are not established. This review focuses on CD19 as a target for DLBCL treatment, discussing clinical trials of tafasitamab, loncastuximab tesirine, and blinatumo-mab, and the potential of re-challenging with anti-CD19 therapies post-CAR T cells.

BLOOD REVIEWS (2023)

添加到收藏夹

Article Hematology

Five-year follow-up of ZUMA-1 supports the curative potential of axicabtagene ciloleucel in refractory large B-cell lymphoma

Sattva S. Neelapu et al.

Summary: In the phase 2 trial ZUMA-1, long-lasting responses were observed in refractory large B-cell lymphoma patients treated with axicabtagene ciloleucel (axi-cel) autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy after 5 years of follow-up. The study showed an objective response rate of 83% and a median overall survival of 25.8 months, with ongoing responses in 31% of patients at data cutoff. No new safety concerns were identified, and B-cell recovery was observed in the majority of patients. These findings highlight the potential effectiveness of axi-cel in aggressive B-cell lymphomas.

BLOOD (2023)

添加到收藏夹

Review Hematology

How I treat refractory/relapsed diffuse large B-cell lymphomas with CD19-directed chimeric antigen receptor T cells

Arnon Nagler et al.

Summary: Chimeric antigen receptor (CAR) T cells targeting CD19 have shown promise as salvage immunotherapy for relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL), with approximately 40% long-term responses. However, treating patients with R/R DLBCL using CAR T-cell therapy poses challenges in terms of diagnosis and therapeutic choices. Recent advancements in understanding CAR T-cell failure mechanisms and the availability of novel immunotherapeutic agents for R/R DLBCL require a rational approach to selecting the appropriate bridging therapy and managing post-CAR T-cell therapy relapses. Additionally, the importance of post-treatment biopsy is emphasized due to the potential for false-positive interpretations from positron emission tomography/computerised tomography scans.

BRITISH JOURNAL OF HAEMATOLOGY (2023)

添加到收藏夹

Review Oncology

CAR T-cell therapy in large B cell lymphoma

Alexander P. Boardman et al.

Summary: CD19-targeted CAR T-cell therapy has revolutionized the treatment of lymphoid malignancies, particularly LBCL. After successful clinical trials, three CD19-CAR T-cell products have received regulatory approval for use in lymphoma patients. Additionally, studies have expanded the use of CAR T-cell therapy to high-risk patients and have shown promising results in CNS lymphoma. This article provides a detailed overview of the clinical data supporting the use of CAR T-cells in LBCL patients.

HEMATOLOGICAL ONCOLOGY (2023)

添加到收藏夹

Article Medicine, General & Internal

Survival with Axicabtagene Ciloleucel in Large B-Cell Lymphoma

Jason R. Westin et al.

Summary: In this study, patients with early relapsed or refractory large B-cell lymphoma who received axicabtagene ciloleucel (axi-cel) as second-line treatment had significantly longer overall survival than those who received standard care, according to a 47.2-month follow-up.

NEW ENGLAND JOURNAL OF MEDICINE (2023)

添加到收藏夹

Article Oncology

Determinants of resistance to engineered T cell therapies targeting CD19 in large B cell lymphomas

Brian J. Sworder et al.

Summary: This study investigates the resistance of anti-CD19 chimeric antigen receptor (CAR19) T cells in relapsed/refractory large B-cell lymphoma (r/rLBCL) patients. By analyzing longitudinal samples from two independent cohorts, it identifies multiple gene alterations associated with resistance, such as B cell identity genes (PAX5 and IRF8), immune checkpoint genes (CD274), and genes affecting the tumor microenvironment (TMEM30A). It also reveals that somatic tumor alterations affect CAR19 therapy at various levels, including CAR19 T cell expansion, persistence, and tumor microenvironment. These findings have implications for improving CAR T cells and personalized therapeutic approaches.

CANCER CELL (2023)

添加到收藏夹

Review Oncology

Cellular therapy in lymphoma

Anna Sureda et al.

Summary: CD19-directed CAR T-cell therapy has had a significant impact on high-risk B-cell non-Hodgkin lymphoma, leading to the development of new areas in medicine, investigation into toxicity risks, mechanisms of resistance, development of novel products and strategies, and addressing issues related to global access and healthcare economics. This article, written by an international community of lymphoma experts who are also women, provides a survey of these areas in the rapidly evolving field of CAR T-cell therapy.

HEMATOLOGICAL ONCOLOGY (2023)

添加到收藏夹

Article Oncology

The AntiCD19 Antibody Drug Immunoconjugate Loncastuximab Achieves Responses in DLBCL Relapsing After AntiCD19 CAR-T Cell Therapy

Paolo F. Caimi et al.

Summary: The antibody loncastuximab tesirine, which targets CD19 surface antigen, has shown efficacy in patients with disease progression after CAR-T cell therapy. Six out of thirteen patients (46%) had a treatment response with median overall survival, progression-free survival, and duration of response of 8.2, 1.4, and 8 months, respectively. Loncastuximab tesirine may be considered as a treatment option for these patients.

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2022)

添加到收藏夹

Article Oncology

Single-Agent Mosunetuzumab Shows Durable Complete Responses in Patients With Relapsed or Refractory B-Cell Lymphomas: Phase I Dose-Escalation Study

Lihua E. Budde et al.

Summary: This study evaluated the safety, tolerability, and efficacy of mosunetuzumab in patients with relapsed or refractory B-cell non-Hodgkin lymphomas (B-NHLs). The results showed that mosunetuzumab has a manageable safety profile and induces durable complete responses in some patients.

JOURNAL OF CLINICAL ONCOLOGY (2022)

添加到收藏夹

Letter Oncology

CD19 expression is maintained in DLBCL patients after treatment with tafasitamab plus lenalidomide in the L-MIND study

Johannes Duell et al.

LEUKEMIA & LYMPHOMA (2022)

添加到收藏夹

Letter Oncology

CD19 epitope masking by tafasitamab leads to delays in subsequent use of CD19 CAR T-cell therapy in two patients with aggressive mature B-cell lymphomas

Kelly N. Fitzgerald et al.

LEUKEMIA & LYMPHOMA (2022)

添加到收藏夹

Article Medicine, General & Internal

Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma

M. R. Bishop et al.

Summary: Tisagenlecleucel did not demonstrate superiority over standard salvage therapy in this trial. Further studies are needed to evaluate which patients may benefit the most from each approach.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

添加到收藏夹

Article Medicine, General & Internal

Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma

F. L. Locke et al.

Summary: This international phase 3 trial showed that axicabtagene ciloleucel therapy significantly improved event-free survival and response in patients with early relapsed or refractory large B-cell lymphoma compared to standard care, despite the expected high-grade toxic effects.

NEW ENGLAND JOURNAL OF MEDICINE (2022)

添加到收藏夹

Article Hematology

GLA/DRST real-world outcome analysis of CAR T-cell therapies for large B-cell lymphoma in Germany

Wolfgang A. Bethge et al.

Summary: A study conducted in Germany suggests that important outcome determinants of CD19-directed CAR T-cell treatment of LBCL in the real-world setting include bridging success, CAR-T product selection, LDH levels, and the absence of prolonged neutropenia and/or severe neurotoxicity.

BLOOD (2022)

添加到收藏夹

Article Oncology

Matching-adjusted Indirect Comparison of the Efficacy of Loncastuximab Tesirine Versus Treatment in the Chemoimmunotherapy Era for Relapsed/Refractory Diffuse Large B-cell Lymphoma

Mehdi Hamadani et al.

Summary: In the absence of head-to-head clinical trials, this study used matching-adjusted indirect comparison to evaluate the relative efficacy of Lonca and CIT-era treatment in patients with relapsed/refractory diffuse large B-cell lymphoma. The results showed that Lonca was associated with significantly higher overall response rate and prolonged overall survival compared to CIT-era treatment.

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2022)

添加到收藏夹

Article Hematology

Resistance to PI3Kδ inhibitors in marginal zone lymphoma can be reverted by targeting the IL-6/PDGFRA axis

Alberto J. Arribas et al.

Summary: In this study, a model of secondary resistance to PI3K delta inhibitors was developed by exposing a splenic MZL cell line to idelalisib. The resistant cells showed upregulated genes, low-methylated promoters, and repression of certain miRNAs. Drug compounds targeting these pathways were found to be effective in the resistant cells. These findings suggest new therapeutic approaches to enhance the antitumor activity of PI3K delta inhibitors in B-cell lymphoid tumors.

HAEMATOLOGICA (2022)

添加到收藏夹

Article Oncology

Comparing apples and oranges: The ZUMA-7, TRANSFORM and BELINDA trials

Come Bommier et al.

Summary: In December 2021, three phase III trials investigating CAR T-cell therapy for large B-cell lymphoma showed discrepant results. Differences in event definition, assessment time, and manufacturing time of CAR-T cells may have contributed to these discrepancies. Improvements can be made by prioritizing progression-free survival as an endpoint and reducing the manufacturing time of CAR-T cells.

HEMATOLOGICAL ONCOLOGY (2022)

添加到收藏夹

Review Oncology

Targeting CD19 in diffuse large B-cell lymphoma: An expert opinion paper

Sarah Bailly et al.

Summary: CD19 as a therapeutic target has advantages in terms of early expression, efficient internalization, limited off-target effects, and high disease specificity, especially in patients with relapsed or refractory B-cell non-Hodgkin lymphoma. However, limited knowledge exists regarding the sequencing of anti-CD19 therapies.

HEMATOLOGICAL ONCOLOGY (2022)

添加到收藏夹

Article Education, Scientific Disciplines

Sequencing therapy in relapsed DLBCL

Christopher R. Flowers et al.

Summary: Diffuse large B-cell lymphoma (DLBCL) is the most common lymphoid malignancy worldwide. Although modern therapy has improved the outcomes for DLBCL patients, a portion of patients are refractory to first-line therapy and need to explore alternative treatments. Flexible communication with patients is crucial to improving treatment effectiveness and patient experience.

HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM (2022)

添加到收藏夹

Article Hematology

Outcomes of patients with aggressive B-cell lymphoma after failure of anti-CD19 CAR T-cell therapy: a DESCAR-T analysis

Roberta Di Blasi et al.

Summary: Anti-CD19 CAR T-cell therapy is a major advance in the treatment of relapsed/refractory aggressive B-cell lymphomas, but a significant number of patients experience treatment failure. Patients who fail after CAR T-cell treatment have a poor prognosis, highlighting the need for further therapeutic strategies.

BLOOD (2022)

添加到收藏夹

Letter Medicine, General & Internal

Five-Year Outcomes for Refractory B-Cell Lymphomas with CAR T-Cell Therapy

Elise A. Chong et al.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

添加到收藏夹

Article Oncology

Real World Evidence of CAR T-Cell Therapies for the Treatment of Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma: A Monocentric Experience

Beatrice Casadei et al.

Summary: Large B-cell lymphomas (LBCL) are the most common types of non-Hodgkin lymphoma, and CD19 CAR T-cell therapies have been approved for treating relapsed/refractory LBCL patients, showing a manageable safety profile and high objective response rate in the standard of care setting.

CANCERS (2021)

添加到收藏夹

Article Oncology

Glofitamab, a Novel, Bivalent CD20-Targeting T-Cell-Engaging Bispecific Antibody, Induces Durable Complete Remissions in Relapsed or Refractory B-Cell Lymphoma: A Phase I Trial

Martin Hutchings et al.

Summary: The study evaluated the use of glofitamab in relapsed or refractory B-cell non-Hodgkin lymphoma (B-NHL) patients. The results showed favorable activity of glofitamab in patients with predominantly refractory, aggressive B-NHL, with frequent and durable complete responses and a predictable and manageable safety profile.

JOURNAL OF CLINICAL ONCOLOGY (2021)

添加到收藏夹

Article Hematology

CD19 target evasion as a mechanism of relapse in large B-cell lymphoma treated with axicabtagene ciloleucel

Vicki Plaks et al.

BLOOD (2021)

添加到收藏夹

Article Hematology

Long-term outcomes from the phase II L-MIND study of tafasitamab (MOR208) plus lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma

Johannes Duell et al.

Summary: The combination therapy of Tafasitamab with lenalidomide showed good efficacy, long-term effectiveness, and well-defined safety profile in patients with relapsed/refractory DLBCL. The consistent efficacy results were observed across different subgroups of patients.

HAEMATOLOGICA (2021)

添加到收藏夹

Article Hematology

Outcomes of older patients in ZUMA-1, a pivotal study of axicabtagene ciloleucel in refractory large B-cell lymphoma

Sattva S. Neelapu et al.

BLOOD (2020)

添加到收藏夹

Editorial Material Hematology

TO THE EDITOR: CD19 antibody-drug conjugate therapy in DLBCL does not preclude subsequent responses to CD19-directed CAR T-cell therapy COMMENT

Bicky Thapa et al.

BLOOD ADVANCES (2020)

添加到收藏夹

Article Hematology

Predictive factors of early progression after CAR T-cell therapy in relapsed/refractory diffuse large B-cell lymphoma

Laetitia Vercellino et al.

BLOOD ADVANCES (2020)

添加到收藏夹

Article Hematology

Resistance to PI3K delta inhibitors in marginal zone lymphoma can be reverted by targeting the IL-6/PDGFRA axis

Alberto J. Arribas et al.

HAEMATOLOGICA (2020)

添加到收藏夹

Article Hematology

The novel CD19-targeting antibody-drug conjugate huB4-DGN462 shows improved anti-tumor activity compared to SAR3419 in CD19-positive lymphoma and leukemia models

Stuart W. Hicks et al.

HAEMATOLOGICA (2019)

添加到收藏夹

Article Hematology

THE ANTIBODY-DRUG CONJUGATE (ADC) LONCASTUXIMAB TESIRINE (ADCT-402) TARGETING CD19 SHOWS STRONG IN VITRO ANTI-LYMPHOMA ACTIVITY BOTH AS SINGLE AGENTS AND IN COMBINATION

C. Tarantelli et al.

HEMATOLOGICAL ONCOLOGY (2019)

添加到收藏夹

Article Oncology

Late Relapses in Patients With Diffuse Large B-Cell Lymphoma Treated With Immunochemotherapy

Yucai Wang et al.

JOURNAL OF CLINICAL ONCOLOGY (2019)

添加到收藏夹

Article Medicine, General & Internal

Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Stephen J. Schuster et al.

NEW ENGLAND JOURNAL OF MEDICINE (2019)

添加到收藏夹

Article Hematology

Long-term outcome of patients with relapsed/refractory B-cell non-Hodgkin lymphoma treated with blinatumomab

Vera Dufner et al.

BLOOD ADVANCES (2019)

添加到收藏夹

Letter Hematology

Sequential loss of tumor surface antigens following chimeric antigen receptor T-cell therapies in diffuse large B-cell lymphoma

Haneen Shalabi et al.

HAEMATOLOGICA (2018)

添加到收藏夹

Article Medicine, General & Internal

Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia

S. L. Maude et al.

NEW ENGLAND JOURNAL OF MEDICINE (2018)

添加到收藏夹

Letter Hematology

Sequential loss of tumor surface antigens following chimeric antigen receptor T-cell therapies in diffuse large B-cell lymphoma

Haneen Shalabi et al.

HAEMATOLOGICA (2018)

添加到收藏夹

Article Medicine, General & Internal

Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma

S. S. Neelapu et al.

NEW ENGLAND JOURNAL OF MEDICINE (2017)

添加到收藏夹

Article Oncology

Bispecific T-Cell Engager (BiTE) Antibody Construct Blinatumomab for the Treatment of Patients With Relapsed/Refractory Non-Hodgkin Lymphoma: Final Results From a Phase I Study

Maria-Elisabeth Goebeler et al.

JOURNAL OF CLINICAL ONCOLOGY (2016)

添加到收藏夹

Article Cell Biology

Anti-CD20/CD3 T cell-dependent bispecific antibody for the treatment of B cell malignancies

Liping L. Sun et al.

SCIENCE TRANSLATIONAL MEDICINE (2015)

添加到收藏夹

Article Oncology

Salvage Regimens With Autologous Transplantation for Relapsed Large B-Cell Lymphoma in the Rituximab Era

Christian Gisselbrecht et al.

JOURNAL OF CLINICAL ONCOLOGY (2010)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.